Investor's Business Daily

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results·Investor's Business Daily

ALLISON GATLIN

Thu, Mar 21, 2024, 2:45 PM2 min read

In this article:

Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.

Continue reading

Advertisement